Addus HomeCare (NASDAQ:ADUS) Stock Rating Raised to "Strong-Buy" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Addus HomeCare to “Strong-Buy” from “Buy.” Across analysts, the stock holds a “Moderate Buy” consensus rating with an average price target of $134.70, though recent recommendations are mixed.
• Addus reported quarterly earnings of $1.83 per share, above the $1.79 consensus, while revenue rose 7% year over year to $387.74 million—slightly below estimates.
• UBS raised its price target to $160 and TD Cowen to $145, both maintaining Buy ratings. Addus also expects to close its AccentCare acquisition in the first quarter of 2027.

Addus HomeCare (NASDAQ:ADUS - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report issued on Saturday, Wall Street Zen reports.

A number of other research firms have also weighed in on ADUS. Barclays boosted their price target on shares of Addus HomeCare from $96.00 to $101.00 and gave the stock an "underweight" rating in a research report on Wednesday. Weiss Ratings upgraded shares of Addus HomeCare from a "hold (c)" rating to a "hold (c+)" rating in a report on Thursday, September 24th. UBS Group raised their target price on shares of Addus HomeCare from $145.00 to $160.00 and gave the stock a "buy" rating in a research note on Thursday. Citigroup lowered Addus HomeCare from a "market outperform" rating to a "neutral" rating in a research report on Monday, September 14th. Finally, Bank of America cut Addus HomeCare from a "buy" rating to a "neutral" rating and cut their price target for the company from $140.00 to $125.00 in a report on Monday, September 14th. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $134.70.

Addus HomeCare Stock Down 2.0%

ADUS stock opened at $124.31 on Friday. Addus HomeCare has a 52 week low of $87.95 and a 52 week high of $131.59. The company has a quick ratio of 1.69, a current ratio of 1.69 and a debt-to-equity ratio of 0.05. The firm has a 50-day simple moving average of $117.60 and a 200-day simple moving average of $106.88. The stock has a market capitalization of $2.32 billion, a P/E ratio of 20.72, a P/E/G ratio of 1.79 and a beta of 0.75.

Addus HomeCare (NASDAQ:ADUS - Get Free Report) last announced its earnings results on Tuesday, November 3rd. The company reported $1.83 EPS for the quarter, beating analysts' consensus estimates of $1.79 by $0.04. Addus HomeCare had a return on equity of 9.96% and a net margin of 7.13%. The business had revenue of $387.74 million during the quarter, compared to analysts' expectations of $388.72 million. During the same quarter in the prior year, the firm earned $1.56 earnings per share. The business's revenue was up 7.0% compared to the same quarter last year. Equities analysts forecast that Addus HomeCare will post 6.34 earnings per share for the current fiscal year.

Institutional Trading of Addus HomeCare

Institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Addus HomeCare during the second quarter worth approximately $344,153,000. Dimensional Fund Advisors LP raised its stake in shares of Addus HomeCare by 11.8% in the first quarter. Dimensional Fund Advisors LP now owns 744,127 shares of the company's stock worth $69,689,000 after acquiring an additional 78,415 shares during the last quarter. Bank of America Corp DE acquired a new stake in Addus HomeCare during the 2nd quarter worth $35,527,000. TimesSquare Capital Management LLC acquired a new position in Addus HomeCare during the second quarter valued at approximately $31,502,000. Finally, Punch & Associates Investment Management Inc. bought a new position in shares of Addus HomeCare in the second quarter valued at about $20,911,000. 95.35% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Addus HomeCare

Here are the key news stories impacting Addus HomeCare this week:

• Positive Sentiment: UBS raised its price target to $160 from $145 and maintained a Buy rating; TD Cowen lifted its target to $145 from $131 and also maintained a Buy rating. UBS price-target report TD Cowen price-target report
• Positive Sentiment: ADUS recently reached a 52-week high. Its latest quarterly results included earnings per share of $1.83, ahead of the $1.79 consensus, while revenue increased 7% year over year. Addus hits a 12-month high
• Positive Sentiment: The company said it expects to close its AccentCare acquisition in the first quarter of 2027 and anticipates a full-year adjusted EBITDA margin around 13%; the deal may offer a growth opportunity, though execution remains ahead. AccentCare update
• Neutral Sentiment: Recent Zacks pieces discuss ADUS’s momentum and value-investing appeal, but the available summaries do not provide specific ratings or new estimates. Zacks momentum article Zacks value article
• Negative Sentiment: Quarterly revenue of $387.74 million was slightly below analysts’ $388.72 million estimate, tempering the otherwise positive earnings beat. Q3 earnings call highlights

Addus HomeCare Company Profile

Addus HomeCare Inc NASDAQ: ADUS provides in-home personal care, hospice and home health services to older adults, people with disabilities and other individuals who need assistance with daily living or medical care. Its services are designed to help clients remain safely and independently in their homes while supporting families and caregivers.

The company's personal care services include assistance with bathing, dressing, grooming, meal preparation, housekeeping and other activities of daily living.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.